Trial Profile
A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2018
Price :
$35
*
At a glance
- Drugs Micafungin (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- Sponsors Astellas Pharma; Astellas Pharma China
- 11 Jan 2016 New trial record